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Adding a long-acting b2-agonist (LABA) by dry powder inhaler (DPI) to tiotropium provides
signiﬁcantly increased and sustained bronchodilation in chronic obstructive pulmonary
disease (COPD) patients over either product alone. To demonstrate similar beneﬁts with a
nebulized LABA, a placebo-controlled trial was conducted to evaluate the efﬁcacy and
safety of formoterol fumarate inhalation solution in subjects receiving tiotropium as a
maintenance treatment for COPD.
After a 7–14-day screening period using tiotropium 18 mg once daily, subjects with
diagnosed COPD (X25% to o65% predicted FEV1) were randomized to receive 20 mg
formoterol fumarate inhalation solution twice daily for nebulization plus tiotropium
(FFIS/TIO) or nebulized placebo twice daily plus tiotropium (PLA/TIO) for 6 weeks. Efﬁcacy
was assessed with spirometry at each visit (Day 1, Week 1, 3, 6), the transition dyspnea
index (TDI), and St. George’s Respiratory Questionnaire (SGRQ).
Baseline characteristics were comparable, including mean FEV1% predicted. At Week 6,
FEV1 AUC0–3 was 1.52 L for FFIS/TIO-treated subjects vs. 1.34 L for PLA/TIO-treated
subjects (po0.0001). The mean TDI scores in the FFIS/TIO and PLA/TIO groups were 2.30
and 0.16, respectively (p ¼ 0.0002). SGRQ did not change signiﬁcantly with 6 weeks
treatment, with the exception of FFIS/TIO improvements in symptom score vs. PLA/TIO
(p ¼ 0.04). More PLA/TIO- than FFIS/TIO-treated subjects experienced AEs (39.7% vs.
22.9%), COPD exacerbations (7.9% vs. 4.5%), and serious AEs (3.2% vs. 1.5%).Elsevier Ltd. All rights reserved.
794 9107; fax: +1 310 206 5088.
ucla.edu (D.P. Tashkin).
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D.P. Tashkin et al.480Nebulized formoterol fumarate in combination with tiotropium provided statistically and
clinically signiﬁcant improvements in bronchodilation and symptom control over
tiotropium alone and demonstrated good tolerability.
& 2008 Elsevier Ltd. All rights reserved.Introduction
Patients with chronic obstructive pulmonary disease (COPD)
suffer from airﬂow obstruction that is partially reversible and
responds to bronchodilator treatment. The Global Initiative
for Chronic Obstructive Lung Disease (GOLD) guidelines1
recommend a stepwise approach to disease management that
includes long-acting bronchodilators as a critical therapeutic
component. Because of the different pharmacological and
clinical proﬁles of the two major classes of long-acting
bronchodilators, b-agonists (LABA) and anticholinergics, it
has been suggested that combination therapy would provide
additive beneﬁts over treatment with one agent alone,2
similar to that seen with combinations of short-acting
bronchodilators.3 The enhanced effect may be attributed to
complementary pharmacodynamic proﬁles whereby tiotro-
pium induces prolonged bronchodilation and formoterol
contributes a rapid onset with greater peak effect.4,5
The effectiveness and safety of the LABA, formoterol
fumarate, in providing rapid and maintained bronchodilation
to patients with COPD has been demonstrated in several
large well-controlled studies using the dry powder inhaler
(DPI), Foradils,6–8 and the recently introduced formulation
of formoterol fumarate for nebulization, PerforomistTM
inhalation solution.9–12 Bronchodilation can also be effec-
tively provided to COPD patients with the long-acting
anticholinergic, tiotropium (Spirivas).13–15
More recently, studies combining formoterol DPI and
tiotropium therapy have been conducted in COPD patients.
Small crossover studies16–18 and one randomized double-
blind, placebo-controlled, parallel group study19 in patients
with stable COPD have demonstrated improvements in
respiratory function and rescue medication use compared
with either agent alone.
Nebulized solutions of long-acting bronchodilators pro-
vide an alternative to DPI and MDI delivery, particularly for
COPD patients, for some of whom nebulized therapy has
been found to provide patient satisfaction20 and quality of
life beneﬁts when used either alone or in combination with a
hand-held device.21 To demonstrate similar beneﬁts with a
nebulized LABA, the present randomized, double-blind,
placebo-controlled study was conducted to evaluate the
efﬁcacy and safety of adding formoterol fumarate inhalation
solution to tiotropium maintenance treatment in patients
with stable COPD.Methods
Subjects
Adult males and females440 years of age who were current
or former smokers (410 pack years) with a diagnosis of
COPD,1 including chronic cough, sputum production, and/orshortness of breath on effort were recruited. Subjects were
excluded if they were pregnant or of child-bearing potential
not using adequate contraception or had a diagnosis of asthma
or atopy, signiﬁcant cormorbidities, radiation or chemother-
apy within 12 months, lung resection, COPD exacerbation
within 60 days, respiratory tract infection within 30 days,
myocardial infarction within 6 months, or an ECG with a
QTc 40.46 s. Subjects requiring long-term oxygen therapy
(412h/day), monoamine oxidase inhibitors, high-dose oral
corticosteroids (equivalent to 410mg/day prednisone) or
non-selective beta-blockers were also excluded.
At screening, subjects were required to have a post-
bronchodilator FEV1 X25% and o65% of predicted normal22
and an FEV1/FVC ratio o0.70. To be enrolled into the
double-blind study, subjects were required to have a pre-
dose FEV1 o70% predicted at the randomization visit.
Study design and treatments
The study was approved by an institutional review board and
conducted in accordance with the Declaration of Helsinki;
all subjects provided written informed consent. The study
used a randomized, double-blind, placebo-controlled, par-
allel group design preceded by a 7–14-day run-in period
during which subjects received once-daily treatment with
tiotropium bromide inhalation powder (TIO, Spirivas, 18 mg,
Boehringer Ingelheim Pharmaceuticals, Ridgeﬁeld, CT)
administered with a HandiHalers. Following randomization,
subjects entered a 6-week double-blind treatment period to
evaluate the efﬁcacy and safety of formoterol fumarate
inhalation solution (FFIS, PerforomistTM inhalation solution,
20 mg/2mL, Dey, L.P., Napa, CA) delivered by the PARI LCs
Plus jet nebulizer with PARI PRONEBs compressor compared
with nebulized placebo delivered from the same device
(PLA), while maintaining once-daily treatment with TIO.
Treatment with TIO always preceded treatment with FFIS or
PLA. Noncompliance with treatment was deﬁned aso80% or
4120% of prescribed study drug administration and could
result in discontinuation from the study.
During both the run-in and double-blind treatment
periods, subjects were not allowed to use other long-acting
bronchodilators or anticholinergics, theophylline or other
methylxanthines, or nedocromil or cromolyn sodium. Nasal
or inhaled corticosteroids as well as oral corticosteroids
(equivalent to p10mg/day prednisone) were allowed if
dosing was stable from 1 month prior to screening. Albuterol
sulfate MDI (90mcg/puff) was provided for as-needed
bronchodilator rescue medication use.
Measurements
At the Screening visit, pre- and 30min post-bronchodilator
spirometry, medical history, physical examination, 12-lead
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subjects entered a 7–14-day run-in during which they were
provided with open-label TIO as well as albuterol rescue
medication. At the randomization visit, eligible subjects
were assigned 1:1 to receive FFIS or PLA twice daily by
nebulization in addition to maintaining their once-daily
treatment with TIO for 6 weeks. At that visit, pre-dose and
post-dose ECGs were performed and the St. George’s
Respiratory Questionnaire (SGRQ)23 and the computerized
version of the baseline dyspnea index (BDI)24 were adminis-
tered. Spirometry was performed approximately 30 and
5min pre-dose; the two highest FEV1 values were averaged
for the mean baseline value. Spirometry was performed at 5
and 30min, 1, 2, and 3 h post-dose. The end of nebulization
was considered Time 0 for post-dose spirometry measure-
ments. Subjects returned to the clinic for visits after 1, 3,
and 6 weeks for spirometry, safety assessments and
collection of diary cards containing self reports of study
and rescue medication use and symptom scores. At the ﬁnal
Week 6 visit, pre- and post-dose ECGs and spirometry were
conducted as at the randomization visit. At Week 6 or early
termination, the SGRQ, the computerized version of the
transitional dyspnea index (TDI),24 and the patient satisfac-
tion and preference questionnaire (PASAPQ)25 were admi-
nistered.Statistical analysis
The primary efﬁcacy endpoint was standardized area under
the curve for FEV1 over 3 h (FEV1 AUC0–3) at the last visit
(Week 6/ET). The FEV1 AUC0–3 calculation included the pre-
dose value and subsequent timepoints; it was computed
using the linear trapezoidal rule and analyzed by ANCOVA.
The last observation carried forward (LOCF) method wasFigure 1 Subjecused for subjects with missing efﬁcacy data except for the
primary variable. The intention-to-treat population (ITT),
comprised all randomized subjects with at least one
evaluable post-randomization measurement, was used for
evaluating all efﬁcacy variables. The safety variables were
evaluated using the safety population, which included all
randomized subjects treated with at least one dose of study
medication. A sample size of 128 patients was required for
randomization, based on demonstrating a difference of
0.100 L in FEV1 AUC0–3 between the two treatment groups at
Week 6/ET with 80% power and a two-sided a of 0.05,
assuming a common standard deviation of 0.200 L.
Results
Baseline demographics and pulmonary function
Of the 185 screened subjects, 130 were randomized to study
treatment (Figure 1). Eight subjects were discontinued in
each treatment group. Demographics of each group are
described in Table 1. The mean age was approximately 65
years, and two-third of the subjects were male. More
subjects in the FFIS/TIO group were current smokers (42%)
compared with the PLA/TIO group (32%), and almost all
subjects were Caucasian (98%). The groups were well
balanced with respect to baseline pulmonary function, with
38.4% predicted FEV1 overall, and there were no statistically
signiﬁcant differences in demographics or pulmonary func-
tion between groups at baseline.
Spirometry
Results of the summary data from pre-dose and 3-h post-
dose measurement of FEV1 AUC0–3 and FVC AUC0–3 are shownt disposition.
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Table 1 Baseline demographics and pulmonary function.
FFIS/TIO (n ¼ 66) PLA/TIO (n ¼ 63) Total (n ¼ 129)
Age, years (S.D.) 65.4 (8.0) 65.8 (8.7) 65.6 (8.3)
Gender, n (%)
Male 45 (68) 42 (67) 87 (67)
Female 21 (32) 21 (33) 42 (33)
Current smoker, n (%) 28 (42) 20 (32) 48 (37)
Race, n (%)
Caucasian 63 (96) 63 (100) 126 (98)
Black 3 (4) 0 3 (2)
Asian 0 0 0
Other 0 0 0
FEV1, % predicted (S.D.)
Pre-bronchodilator 37.8 (9.9) 39.0 (10.9) 38.4 (10.4)
Post-bronchodilator 44.2 (10.1) 45.7 (11.2) 44.9 (10.6)
FEV1, L (S.D.)
Pre-bronchodilator 1.17 (0.40) 1.20 (0.44) 1.19 (0.42)
Post-bronchodilator 1.37 (0.40) 1.39 (0.46) 1.38 (0.43)
Post-bronchodilator FEV1/FVC (S.D.) 0.48 (0.08) 0.49 (0.10) 0.49 (0.09)
FFIS/TIO, formoterol fumarate inhalation solution+tiotropium; PLA/TIO, placebo inhalation solution+tiotropium. No signiﬁcant
differences in baseline characteristics occurred between groups.
Table 2 FEV1 and FVC AUC0–3.
FFIS/TIO PLA/TIO
FEV1 AUC0–3, L (S.D.)
Day 1 1.47 (0.46) 1.33 (0.50)
Week 6 1.52 (0.48) 1.34 (0.54)
FVC AUC0–3, L (S.D.)
Day 1 3.06 (0.74) 2.81 (0.98)
Week 6 3.13 (0.78) 2.76 (1.02)
FFIS/TIO, formoterol fumarate inhalation solution+tiotro-
pium; PLA/TIO, placebo inhalation solution+tiotropium.
po0.0001 vs. PLA/TIO.
D.P. Tashkin et al.482in Table 2. The standardized absolute AUC0–3 for FEV1
following the ﬁrst dose of study medication at Day 1 in the
ITT population was signiﬁcantly improved in the FFIS/TIO
group compared with PLA/TIO. FEV1 AUC0–3 remained
signiﬁcantly greater in the FFIS/TIO group after 6 weeks of
treatment without any diminution of effect. The LS mean
difference between FFIS/TIO and PLA/TIO at Week 6 (or
early termination) was 0.185 L (95% CI, 0.102–0.267,
po0.0001). FVC AUC0–3 was also signiﬁcantly improved with
the addition of FFIS to tiotropium compared with placebo at
both Day 1 and Week 6. Figure 2 displays the FEV1
measurements over the 3-h course of spirometry testing.
No improvement in lung function was noted 5min following
administration of PLA/TIO on either Day 1 or Week 6 in
contrast to a signiﬁcant increase in the FFIS/TIO group. FEV1in the FFIS/TIO group remained signiﬁcantly greater than
that in the PLA/TIO group over the remainder of the 3-h
period on both Day 1 and Week 6.
Results from other spirometry analyses are shown in
Table 3. While pre-dose FEV1 (trough) values did not differ
signiﬁcantly between treatment groups, peak FEV1 levels
were signiﬁcantly higher in the FFIS/TIO group compared
with PLA/TIO (po0.0001). FEV1 levels on Day 1 and at Week
6 rose approximately 300mL from trough to peak measure-
ment. Pre-dose FVC was also signiﬁcantly improved at both
Week 1 and Week 6 in the FFIS/TIO group compared with
PLA/TIO (po0.05). Pre-dose inspiratory capacity was not
affected by treatment with FFIS/TIO.Dyspnea
The mean baseline dyspnea score was similar in the two
groups (6.3 and 6.4 in the FFIS/TIO and PLA/TIO groups,
respectively). After 6 weeks of treatment, the mean TDI
scores in the FFIS/TIO and PLA/TIO groups were 2.30 and
0.16, respectively, with a LS mean difference of 1.80 (95%
CI, 0.859–2.740, p ¼ 0.0002). Figure 3 illustrates the fre-
quency distribution of TDI scores in FFIS/TIO and PLA/TIO
subjects. A majority of subjects in the FFIS/TIO group
(57.7%) experienced an improvement in dyspnea from
baseline, including subjects with major (+7 to +9), moderate
(+4 to +6), and mild improvement (+1 to +3), whereas a
majority of subjects in the PLA/TIO group (68.9%) experi-
enced no change or a worsening of dyspnea. No FFIS/TIO-
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Figure 2 Time course of mean FEV1 response after ﬁrst dose (Day 1) and 6 weeks of treatment in the ITT population. FFIS/TIO ¼
formoterol fumarate inhalation solution 20 mg BID and tiotropium bromide inhalation powder 18 mg QD, PLA/TIO ¼ placebo inhalation
solution BID and tiotropium bromide inhalation powder 18 mg QD. Data expressed as LS means adjusted for baseline FEV1.
*pp0.0003
vs. PLA/TIO.
Table 3 Spirometry measurements.
FFIS/TIO PLA/TIO
Pre-dose (trough) FEV1, L (S.D.)
Day 1 1.26 (0.44) 1.27 (0.49)
Week 1 1.32 (0.42) 1.26 (0.48)
Week 3 1.38 (0.79) 1.28 (0.50)
Week 6 1.32 (0.47) 1.28 (0.48)
Peak FEV1, L (S.D.)
Day 1 1.57 (0.47) 1.42 (0.51)
Week 6 1.61 (0.49) 1.42 (0.54)
Pre-dose FVC, L (S.D.)
Day 1 2.59 (0.76) 2.67 (0.93)
Week 1 2.76 (0.76) 2.68 (0.89)
Week 3 2.70 (0.70) 2.68 (0.93)
Week 6 2.74 (0.77) 2.66 (0.97)
Pre-dose IC, L (S.D.)
Day 1 2.18 (0.69) 2.20 (0.67)
Week 6 2.29 (0.74) 2.24 (0.72)
FFIS/TIO, formoterol fumarate inhalation solution+tiotro-
pium; PLA/TIO, placebo inhalation solution+tiotropium.
po0.0001 vs. PLA/TIO.
po0.05 vs. PLA/TIO.
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Patient-reported respiratory symptoms were similar during
the run-in treatment period in the two groups. By the period
between Week 3 and Week 6 of treatment, shortness ofbreath, chest tightness, night-time awakenings, and the
total respiratory symptom score were all signiﬁcantly
improved in the FFIS/TIO group compared with PLA/TIO
(data provided as a Supplementary Table). Cough scores
did not differ signiﬁcantly in the two groups at any time
during treatment.
Use of rescue albuterol during the 7–14-day run-in period,
during which tiotropium was administered, was similar in
the two treatment groups, averaging 2.4 and 2.8 puffs/day
in the FFIS/TIO and PLA/TIO groups, respectively (Figure 4).
During Week 1, albuterol use declined in the FFIS/TIO group
to 1.3 puffs/day and remained similarly low throughout
treatment, whereas albuterol use in the PLA/TIO group
trended higher throughout the 6 weeks of treatment
(pp0.0001 vs. FFIS/TIO).
Health-related quality of life
SGRQ values at Day 1 were similar between treatment
groups for total score (45.9 overall) as well as the scores for
the symptoms, activity, and impact components. Scores did
not change markedly over the 6 weeks of treatment. The
only statistically signiﬁcant and clinically relevant treat-
ment difference that was observed with FFIS/TIO compared
with PLA/TIO was an improved change from baseline in
symptom score, which changed by a LS mean of 5.8 units in
FFIS/TIO-treated subjects vs. +0.5 units in the PLA/TIO
group (p ¼ 0.04, 95% CI, 12.2 to 0.35).
Compliance and device utilization
Throughout the study, compliance was high in both the
FFIS/TIO and PLA/TIO groups and with both the HandiHaler
























Figure 4 Mean daily albuterol use, puffs/day. FFIS/TIO ¼ formoterol fumarate inhalation solution 20 mg BID and tiotropium bromide
























Figure 3 Frequency distribution of TDI scores. FFIS/TIO ¼ formoterol fumarate inhalation solution 20 mg BID and tiotropium
bromide inhalation powder 18 mg QD, PLA/TIO ¼ placebo inhalation solution BID and tiotropium bromide inhalation powder 18 mg QD.
Mild, moderate, and major improvement indicates TDI scores of +1 to +3, +4 to +6, and +7 to +9, respectively; mild, moderate and
major worsening indicates TDI scores of 1 to 3, 4 to 6, and 7 to 9, respectively.
D.P. Tashkin et al.484during Weeks 1–3 (84%) and was above 90% throughout the
rest of the study irrespective of device. Using the PASAPQ to
assess device preference at Week 6, the HandiHalers waspreferred over the nebulizer in total score as well as
subscores for performance, convenience, overall satisfac-
tion, and willingness to continue.
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Table 4 Most common adverse events, n (%).
FFIS/TIO PLA/TIO
Subjects with at least 1 AE 16 (23.9) 25 (39.7%)
COPD exacerbation 3 (4.5) 5 (7.9)
Cough 2 (3.0) 1 (1.6)
Pulmonary congestion 0 2 (3.2)
Nasopharyngitis 1 (1.5) 2 (3.2)
Diarrhea 1 (1.5) 2 (3.2)
Vomiting 0 2 (3.2)
Insomnia 0 2 (3.2)
FFIS/TIO, formoterol fumarate inhalation solution+tiotro-
pium; PLA/TIO, placebo inhalation solution+tiotropium.
Events reported by two or more subjects in a treatment
group.
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The most frequent adverse events are shown in Table 4.
Twenty-four percent of FFIS/TIO-treated subjects reported
at least one AE compared with 40% in the PLA/TIO group; 6%
and 13% were assessed as drug-related, respectively. COPD
exacerbations occurred in 4.5% and 7.9% of FFIS/TIO and
PLA/TIO-treated subjects, respectively; those with exacer-
bations lasting at least 3 days and/or requiring oral
corticosteroids and/or antibiotics were discontinued from
the study (6/8) with one (FFIS/TIO) considered to be a
serious adverse event (SAE). Other reasons for discontinua-
tion included dyspnea exacerbations (n ¼ 1, PLA/TIO), chest
pain (n ¼ 1, FFIS/TIO subject also with COPD exacerbation),
acute bronchitis (n ¼ 1, FFIS/TIO), insomnia/psychomotor
hyperactivity (n ¼ 1, PLA/TIO), and insomnia/abnormally
frequent urination (n ¼ 1, PLA/TIO). Two PLA/TIO-treated
subjects experienced SAEs, one with cellulitis and one with
pneumonia. None of the SAEs were considered drug-related,
and all resolved without sequelae.
Most laboratory measures were within normal range at
screening and Week 6. One FFIS/TIO-treated subject
experienced a decrease in serum potassium to 3.1mmol/L.
Electrocardiogram mean heart rate changes at Week 6 for
the post-dose ECG were 0.2 bpm (FFIS/TIO) and 1.5 bpm
(PLA/TIO). Mean post-dose changes in the QTcB interval
were 6.2ms (FFIS/TIO) and 0.6ms (PLA/TIO). Two FFIS/TIO-
treated subjects and one subject in the PLA/TIO group had
maximum changes in QTcB interval X60ms. Changes in PR
interval, RR interval, and QRS duration were unremarkable.
Discussion
In this 6-week placebo-controlled study, nebulized formo-
terol fumarate twice daily provided a clinically meaningful
and statistically signiﬁcant beneﬁt over tiotropium treat-
ment alone to COPD patients on several endpoints con-
sidered important for effective disease management.1,2,26
First, improvements in lung function were more rapid and
signiﬁcantly greater with FFIS/TIO than with tiotropium
alone. Spirometry results after FFIS/TIO treatment, whether
measured by FEV1 AUC0–3, peak FEV1, or trough FVC, all
demonstrated improvements compared with tiotropiumalone, and these improvements were long-lasting, persisting
for the duration of the trial. These improvements were
apparent following the ﬁrst dose of FFIS and were
maintained throughout the 6 weeks of treatment without
evidence of tachyphylaxis. A signiﬁcant bronchodilator
beneﬁt was observed within 5min of FFIS/TIO treatment
compared to PLA/TIO. In addition, the increase in bronch-
odilation observed after FFIS treatment was approximately
300mL and at least 20% over baseline, a clinically relevant
improvement compared with approximately 150mL follow-
ing tiotropium alone.
While mean trough FEV1 numerically improved with
FFIS/TIO compared with tiotropium alone, there were no
statistically signiﬁcant differences between treatments.
These results differ from those reported by others who
found signiﬁcant improvements in trough FEV1 with for-
moterol DPI added to tiotropium.18,19 This disparity could be
due to sampling or statistical power differences between
the present report and previous studies.
No signiﬁcant effect on inspiratory capacity was observed
in this study. In a crossover study, van Noord et al. observed
that, following a 2-week run-in period on tiotropium alone,
add-on formoterol DPI to tiotropium did result in a
signiﬁcant improvement in inspiratory capacity above that
noted with tiotropium alone.18 The reason for the discrepant
results in the present study is not clear. On the other hand,
the observed FVC improvements with added formoterol in
the current study may be an indication of relief of lung
hyperinﬂation.27
Improvements in symptom scores and dyspnea demon-
strate that FFIS treatment not only improved lung function
by objective spirometry measurements but also provided
relief of the troublesome effects of COPD as observed by
patients. On daily diary card ratings, dyspnea, chest
tightness, night-time awakenings, and total symptom scores
were all improved by FFIS treatment vs. tiotropium alone.
Dyspnea has been shown to be an important predictor of
mortality in COPD patients.28 Dyspnea improvement follow-
ing FFIS treatment in the current study was convincingly
demonstrated by the results of dyspnea focal scores. In
addition to statistically signiﬁcant improvements in TDI
for FFIS/TIO vs. treatment with tiotropium alone, the mean
TDI score (+2.3) for the FFIS/TIO group was above that
regarded as clinically relevant (+1),29 and the majority of
FFIS/TIO-treated subjects, but not subjects receiving
tiotropium alone, had improvements greater than 1 unit.
Use of rescue albuterol, another measure of COPD symptoms
and severity, was also further reduced with the addition of
FFIS treatment.
Health status, as measured by SGRQ, was not signiﬁcantly
impacted by FFIS/TIO treatment compared with tiotropium
alone, which has already been shown to have a signiﬁcant
impact on health-related quality of life,15 although there
was a trend toward greater beneﬁt for the FFIS/TIO-treated
subjects. The decline in SGRQ symptom score of 5.8 units
after 6 weeks of FFIS/TIO treatment was a change of
statistical signiﬁcance (p ¼ 0.04) and probable clinical
relevance.23
These study results describing the beneﬁts of adding
nebulized formoterol treatment to tiotropium on efﬁcacy
and safety in COPD patients are very comparable to those of
previous studies using formoterol DPI. From the results of a
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Tashkin and Varghese reported mean treatment differences
in FEV1 AUC0–3 between the formoterol+tiotropium group
and the tiotropium group at Weeks 4 and 8 of 150 and
162mL, respectively19; here we report a mean difference at
the end of study (Week 6) of 185mL. In crossover studies
comparing formoterol DPI BID, tiotropium QD, and the two
drugs together in COPD patients, others have also demon-
strated that combination treatment provides signiﬁcantly
greater improvement in lung function than treatment with
tiotropium alone.16–18 In a pilot study, adding theophylline
as a third agent did not result in statistically signiﬁcant
beneﬁts greater than those achieved with concomitant
formoterol/tiotropium in stable COPD patients.30 Results of
the current study further support data previously reported
indicating the clinical comparability between the nebulized
and DPI formulations of formoterol fumarate.9–12
These results also offer additional insight into the beneﬁt
of concomitant therapy with a LABA and long-acting antic-
holinergic. In reporting outcomes of a large COPD study
evaluating the addition of salmeterol to tiotropium treat-
ment for 1 year, Aaron et al. reported that pre-bronchodi-
lator FEV1 was not signiﬁcantly improved in the
tiotropium+salmeterol group vs. tiotropium alone,31 similar
to our ﬁndings with formoterol. However, Aaron et al. did
not report post-dose results, and it is with these results that
we found signiﬁcant, clinically relevant improvements in
lung function due to the addition of formoterol. In a single-
dose crossover study in COPD patients, Cazzola et al. also
explored the bronchodilator effects of tiotropium vs.
salmeterol vs. the combination,32 but, unlike our study,
these authors did not employ a 2-week tiotropium run-in
period. Because a pharmacodynamic steady state is not
achieved with tiotropium until approximately 8 days,33 the
results on Day 1 of the two studies are not directly
comparable. However, it is notable that maximum increases
in FEV1 reported by Cazzola et al. averaged 290 and 165mL
in the combination and tiotropium alone arms, respec-
tively,32 results that are very similar to the increase of 310
and 150mL for the FFIS/TIO combination and PLA/TIO arms
in our study.
In the current study, compliance was equally high in both
groups of subjects and with both devices. There was no
evidence to suggest twice-daily use of a nebulizer added
inconvenience to maintenance bronchodilator therapy,
given the excellent compliance scores. An attempt was
made to assess device satisfaction using the only device
questionnaire validated at the time of the study.25 Patient
satisfaction and preference was greater with the HandiHa-
lers device than the nebulizer on the PASAPQ. However, this
questionnaire was developed to compare MDI and DPI
devices,25 not to evaluate satisfaction with nebulizers, and
the outcome may have been inﬂuenced by the once-daily
(HandiHalers) vs. twice-daily (nebulizer) administration.
Furthermore, the ability to use both devices adequately was
a requirement for study participation. Evidence-based
guidelines conﬁrm there are no signiﬁcant efﬁcacy or safety
differences among delivery devices, including nebulizers.34
Results of the current placebo-controlled study demon-
strated that concomitant therapy with twice-daily nebulized
formoterol fumarate and once-daily tiotropium pro-
vides statistically signiﬁcant and clinically relevant improve-ments in bronchodilation and COPD symptoms over tiotro-
pium alone.
Conﬂict of interest
The study reported in this manuscript was supported by Dey,
L.P. The authors received compensation as investigators in
the study. In addition, Drs. Tashkin and Littner have served
as advisors to Dey, L.P. L. Tomlinson, M. Rinehart and
Dr. Denis-Mize are employees of Dey, L.P.
Acknowledgments
The authors would like to thank all of the principal
investigators and personnel at these study sites: Charles
Andrews, MD, Diagnostics Research Group, San Antonio, TX;
John Condemi, MD, Allergy Asthma Immunology of Rochester
Research Center, Rochester, NY; Gary Ferguson, MD, PRISM,
Livonia, MI; Charles Fogarty, MD, Spartanburg Pharmaceu-
tical Research, Spartanburg, SC; Joshua Jacobs, MD, Allergy
& Asthma Clinical Research Inc., Walnut Creek, CA; Richard
Kahn, MD, Central Maine Pulmonary Associates, Auburn, ME;
Edward Kerwin, MD, Clinical Research Institute of Southern
Oregon, PC, Medford, OR; Phillip Korenblat, MD, The Clinical
Research Center, LLC, St. Louis, MO; Bernard Levine, MD,
Pulmonary Associates, PA, Phoenix, AZ; Mark Lindley, MD,
ClinSite Inc., Ann Arbor, MI; Michael Littner, MD, Creater Los
Angeles Healthcare Systems, Sepulveda, CA; Lyndon Mans-
ﬁeld, MD, Western Sky Medical Research, El Paso, TX; Robert
Nathan, MD, Asthma and Allergy Associates, PC, Colorado
Springs, CO; Michael Noonan, MD, Transitional Clinical
Research Inc., Portland, OR; Shailen Shah, MD, Allergy,
Asthma & Immunology, Collegeville, PA; Juan Sotomayor,
MD, Medical Research Associates of Central New York,
Liverpool, NY; Barry Streit, MD, Central Medical Group, PA,
Tamarac, FL; Donald Tashkin, MD, UCLA Department of
Medicine, Los Angeles, CA.
The study sponsor was Dey, L.P., Napa, CA. Employees of
Dey were involved in the study design; in the collection,
analysis and interpretation of data; in the writing of the
manuscript; and in the decision to submit the manuscript for
publication. Authors were assisted by a professional medical
writer, Elizabeth Field, Ph.D., in the preparation of the
manuscript.
Appendix A. Supplementary Materials
Supplementary data associated with this article can be found
in the online version at doi:10.1016/j.rmed.2007.12.019.References
1. Global initiative for chronic obstructive lung disease (GOLD).
Report of the GOLD workshop, global strategy for diagnosis,
management and prevention of COPD, 2006 update. Available
at: /http://www.goldcopd.comS.
2. Tashkin DP, Cooper CB. The role of long-acting bronchodilators
in the management of stable COPD. Chest 2004;125:249–59.
3. Combivent Aerosol Study Group. In chronic obstructive pulmon-
ary disease, a combination of ipratropium and albuterol is more
ARTICLE IN PRESS
Nebulized formoterol plus tiotropium for COPD 487effective than either agent alone: an 85-day multicenter trial.
Chest 1994;105:1411–9.
4. Cazzola M, Di Marco F, Santus P, et al. The pharmacodynamic
effects of single inhaled doses of formoterol, tiotropium and
their combination in patients with COPD. Pulm Pharmacol Ther
2004;17:35–9.
5. Richter K, Stenglein S, Mucke M, et al. Onset and duration of
action of formoterol and tiotropium in patients with moderate
to severe COPD. Respiration 2006;73:414–9.
6. Aalbers R, Ayres J, Backer V, et al. Formoterol in patients with
chronic obstructive pulmonary disease: a randomized, con-
trolled, 3-month trial. Eur Respir J 2002;19:936–43.
7. Dahl R, Greefhorst LAPM, Nowak D, et al. Inhaled formoterol;
dry powder versus ipratropium bromide in chronic obstructive
pulmonary disease. Am J Respir Crit Care Med 2001;164:778–84.
8. Rossi A, Kristufek P, Levine B, et al. Comparison of the efﬁcacy,
tolerability, and safety of formoterol dry powder and oral,
slow-release theophylline in the treatment of COPD. Chest
2002;121:1058–69.
9. Gross NJ, Nelson HS, Lapidus RJ, Dunn L, Lynn L, Rinehart M,
et al. Efﬁcacy and safety of formoterol fumarate delivered by
nebulization to COPD patients. Respir Med 2008;102:189–97.
10. Nelson HS, ZuWallack R, Levine B, Kerwin EM, Denis-Mize K,
Rinehart M. Safety proﬁle of formoterol fumarate delivered by
nebulization to COPD patients [abstract]. Am J Respir Crit Care
Med, Abstr Issue 2007;117:A128.
11. Donohue JF, Hanania NA, Fogarty CM, Campbell SC, Denis-Mize
K, Rinehart M. Long-term safety of nebulized formoterol in
COPD: an open-label active-controlled extension study. Chest
2007;132:531S.
12. Nelson HS, Gross NJ, Rinehart M, Denis-Mize K. Cardiovascular
safety of nebulized formoterol: results of a placebo-controlled,
double-blind phase III study. Clin Ther 2007;29:2167–78.
13. Littner MR, Ilowite JS, Tashkin DP, et al. Long-acting bronch-
odilation with once-daily dosing of tiotropium (Spiriva) in stable
chronic obstructive pulmonary disease. Am J Respir Crit Care
Med 2000;161:1136–42.
14. Casaburi R, Briggs DD, Donohue JF, Serby CW, Menjoge SS, Witek
TJ. The spirometric efﬁcacy of once-daily dosing with tiotro-
pium in stable COPD: a 13-week multicenter trial. Chest
2000;118:1294–302.
15. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation
of once-daily inhaled tiotropium in chronic obstructive pulmon-
ary disease. Eur Respir J 2002;19:217–24.
16. Cazzola M, Noschese P, Salzillo A, De Giglio C, D’Amato G,
Matera MG. Bronchodilator response to formoterol after regular
tiotropium or to tiotropium after regular formoterol in COPD
patients. Respir Med 2005;99:524–8.
17. van Noord JA, Aumann J-L, Janssens E, et al. Comparison of
tiotropium once daily, formoterol twice daily and both combined
once daily in patients with COPD. Eur Respir J 2005;20:214–22.
18. van Noord JA, Aumann J-L, Janssens E, et al. Effects of
tiotropium with and without formoterol on airﬂow obstruction
and resting hyperinﬂation in patients with COPD. Chest
2006;129:509–17.19. Tashkin DP, Varghese ST. Formoterol plus tiotropium results in
greater improvements in lung function compared with tiotro-
pium administered alone in patients with COPD [abstract].
J Allergy Clin Immunol 2007;119(Suppl 1):S4 Abstract 13.
20. Barta SK, Crawford A, Roberts CM. Survey of patients’ views of
domiciliary nebuliser treatment for chronic lung disease. Respir
Med 2002;96:375–81.
21. Tashkin DP, Klein GL, Colman SS, Zayed H, Schonfeld WH.
Comparing COPD treatment: nebulizer, metered dose inhaler,
and concomitant therapy. Am J Med 2007;120:435–41.
22. Crapo RO, Morris AH, Gardner RM. Reference spirometric values
using techniques and equipment that meet ATS recommenda-
tions. Am Rev Respir Dis 1981;123:659–64.
23. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-
complete measure for chronic airﬂow limitation—the St.
George’s Respiratory Questionnaire. Am Rev Respir Dis 1992;
145:1321–7.
24. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measure-
ment of dyspnea. Contents, interobserver agreement, and
physiologic correlates of two new clinical indexes. Chest
1984;85:751–8.
25. Kozma CM, Slaton TL, Monz BU, Hodder R, Reese PR.
Development and validation of a patient satisfaction and
preference questionnaire for inhalation devices. Treat Respir
Med 2005;4:41–52.
26. Donohue JF. Minimal clinically important differences in COPD
lung function. J COPD 2005;2:111–24.
27. O’Donnell DE, Fluge T, Gerken F, et al. Effects of tiotropium on
lung hyperinﬂoation, dyspnoea and exercise tolerance in COPD.
Eur Respir J 2004;23:832–40.
28. Oga T, Nishimura K, Mitsuhiro T, Hajiro T, Mishima M. Dyspnoea
with activities of daily living versus peak dyspnoea during
exercise in male patients with COPD. Respir Med 2006;100:
965–71.
29. Witek Jr TJ, Mahler DA. Minimal important difference of the
transition dyspnoea index in a multinational clinical trial. Eur
Respir J 2003;21:267–72.
30. Cazzola M, Matera MG. The additive effect of theophylline on a
combination of formoterol and tiotropium in stable COPD: a
pilot study. Respir Med 2007;101:957–62.
31. Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in
combination with placebo, salmeterol, or ﬂuticasone-salmeter-
ol for treatment of chronic obstructive pulmonary disease. Ann
Int Med 2007;146:545–55.
32. Cazzola M, Centanni S, Santus P, et al. The functional impact of
adding salmeterol and tiotropium in patients with stable COPD.
Respir Med 2004;98:1214–21.
33. van Noord JA, Smeets JJ, Custers FLJ, Korducki L, Cornelissen
PJG. Pharmacodynamic steady state of tiotropium in patients
with chronic obstructive pulmonary disease. Eur Respir J
2002;19:639–44.
34. Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and
outcomes of aerosol therapy: evidence-based guidelines:
American College of Chest Physicians/American College of
Asthma, Allergy, and Immunology. Chest 2005;127:335–71.
